Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Erika, Gurzeler"'
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 10 (2022)
Graphical Abstract
Externí odkaz:
https://doaj.org/article/f86914d9ec104ff798544c8450dc46ba
Autor:
Erika Gurzeler, Anna-Kaisa Ruotsalainen, Anssi Laine, Teemu Valkama, Sanna Kettunen, Markku Laakso, Seppo Ylä-Herttuala
Publikováno v:
PLoS ONE, Vol 16, Iss 11 (2021)
Background and aims Diabetes is a major risk factor of atherosclerosis and its complications. The loss-of-function mutation E1506K in the sulfonylurea receptor 1 (SUR1-E1506K) induces hyperinsulinemia in infancy, leading to impaired glucose tolerance
Externí odkaz:
https://doaj.org/article/95ff50082cac4d4ab98c60aaa8e93e1f
Autor:
Mari Merentie, Riina Rissanen, Line Lottonen-Raikaslehto, Jenni Huusko, Erika Gurzeler, Mikko P Turunen, Lari Holappa, Petri Mäkinen, Seppo Ylä-Herttuala
Publikováno v:
PLoS ONE, Vol 13, Iss 1, p e0190981 (2018)
Vascular endothelial growth factor-A (VEGF-A) is the master regulator of angiogenesis, vascular permeability and growth. However, its role in mature blood vessels is still not well understood. To better understand the role of VEGF-A in the adult vasc
Externí odkaz:
https://doaj.org/article/53147f53257445b287a978129a263daf
Autor:
Nikolay Naumenko, Jenni Huusko, Tomi Tuomainen, Jussi T. Koivumäki, Mari Merentie, Erika Gurzeler, Kari Alitalo, Riikka Kivelä, Seppo Ylä-Herttuala, Pasi Tavi
Publikováno v:
Frontiers in Physiology, Vol 8 (2017)
Vascular endothelial growth factor B (VEGF-B) is a potent mediator of vascular, metabolic, growth, and stress responses in the heart, but the effects on cardiac muscle and cardiomyocyte function are not known. The purpose of this study was to assess
Externí odkaz:
https://doaj.org/article/67b7ea8e91684a2a96e280d6e14ddf63
Autor:
Erika Gurzeler, Henri Niskanen, Jenni Huusko, Einari Aavik, Anssi Laine, Minna U. Kaikkonen, Seppo Ylä-Herttuala, Teemu Valkama
Publikováno v:
Biochimica et Biophysica Acta (BBA) - General Subjects. 1863:481-490
Statins are effective drugs used to prevent and treat cardiovascular diseases but their effects in the absence of low density lipoprotein receptor (LDLR) and on the risk of diabetes are not yet well characterized. The aim of this study was to clarify
Autor:
Ann-Cathrine Jönsson-Rylander, Olga Kotova, Maria F. Gomez, Seppo Ylä-Herttuala, Anna-Maria Dutius Andersson, Lisa Berglund, Suvi E. Heinonen, Erika Gurzeler, Fabiana Blanco
Publikováno v:
Diabetes & Vascular Disease Research
Aims: Despite vast clinical experience linking diabetes and atherosclerosis, the molecular mechanisms leading to accelerated vascular damage are still unclear. Here, we investigated the effects of nuclear factor of activated T-cells inhibition on pla
Autor:
Line Lottonen-Raikaslehto, Mikko P. Turunen, Lari Holappa, Petri I. Mäkinen, Jenni Huusko, Erika Gurzeler, Seppo Ylä-Herttuala, Riina Rissanen, Mari Merentie
Publikováno v:
PLOS ONE
PLoS ONE
PLoS ONE, Vol 13, Iss 1, p e0190981 (2018)
PLoS ONE
PLoS ONE, Vol 13, Iss 1, p e0190981 (2018)
Vascular endothelial growth factor-A (VEGF-A) is the master regulator of angiogenesis, vascular permeability and growth. However, its role in mature blood vessels is still not well understood. To better understand the role of VEGF-A in the adult vasc
Autor:
Thomas L. Theelen, Mat J.A.P. Daemen, Jari P. Lappalainen, Erik A.L. Biessen, Jack P.M. Cleutjens, Marion J.J. Gijbels, Judith C. Sluimer, Erika Gurzeler, Kari Alitalo, Seppo Ylä-Herttuala
Publikováno v:
Atherosclerosis
Atherosclerosis, 241(2), 297-304. Elsevier Ireland Ltd
Atherosclerosis, 241(2), 297-304. Elsevier Ireland Ltd
Objective Angiopoietin-2 (Ang-2) blocking agents are currently undergoing clinical trials for use in cancer treatment. Ang-2 has also been associated with rupture-prone atherosclerotic plaques in humans, suggesting a role for Ang-2 in plaque stabilit
Autor:
Søren K. Moestrup, Galina Dragneva, Christian Brix Folsted Andersen, Jenni Huusko, Marike H. Dijkstra, Erika Gurzeler, Seppo Ylä-Herttuala, Annukka M. Kivelä, Anssi Laine
Publikováno v:
Kivelä, A M, Huusko, J, Gurzeler, E, Laine, A, Dijkstra, M H, Dragneva, G, Andersen, C B F, Moestrup, S K & Ylä-Herttuala, S 2017, ' High Plasma Lipid Levels Reduce Efficacy of Adenovirus-Mediated Gene Therapy ', Scientific Reports, vol. 7, no. 1, pp. 386 . https://doi.org/10.1038/s41598-017-00376-5
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Scientific Reports
Scientific Reports, Vol 7, Iss 1, Pp 1-8 (2017)
Adenoviruses are very efficient vectors for delivering therapeutic genes in preclinical and clinical trials. However, randomized controlled human trials have often been lacking clear clinically relevant results. We hypothesized that high lipid levels
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42e97b6fa4a7773262d4fe1d236740b8
https://erepo.uef.fi/handle/123456789/5011
https://erepo.uef.fi/handle/123456789/5011
Autor:
Erika Gurzeler, Marike H. Dijkstra, Vesa M. Olkkonen, Annukka M. Kivelä, Ulf Eriksson, Suvi E. Heinonen, Jenni Huusko, Petri I. Mäkinen, Matti Jauhiainen, Pia Leppänen, Seppo Ylä-Herttuala
Publikováno v:
Cardiovascular Research. 99:716-723
Aims The role of vascular endothelial growth factor (VEGF-A) in atherogenesis has remained controversial. We addressed this by comparing the effects of adenoviral VEGF-A gene transfer on atherosclerosis and lipoproteins in ApoE−/−, LDLR−/−, L